Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fennec Pharmaceuticals (FENC – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Pfizer (PFE)

Fennec Pharmaceuticals ( ($TSE:FRX) ) has shared an announcement. Fennec Pharmaceuticals announced an investigator-sponsored trial by City of Hope ...

Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment

The latest announcement is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). Fennec Pharmaceuticals announced positive results from a Phase 2/3 clini...

Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fennec Pharmaceuticals (FENC – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Fennec Pharmaceuticals (FENC), Boston Scientific (BSX)

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an update. Fennec Pharmaceuticals has successfully completed the full redemption of its outstandin...

Fennec Pharmaceuticals Completes Full Debt Redemption, Strengthening Financial Position

Fennec Pharmaceuticals ( ($FENC) ) has released its Q3 earnings. Here is a breakdown of the information Fennec Pharmaceuticals presented to its inv...

Fennec Pharmaceuticals Reports Increased PEDMARK Sales

In a report released today, from Wedbush maintained a Buy rating on Fennec Pharmaceuticals, with a price target of $13.00. Currently, the analyst c...

Market Cap	$236.01M	P/E Ratio	N/A
52W High	$9.92	52W Low	$4.68
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	54.8%
Overall Score	34	Value Score	40
Quality Score	52	Technical Score	10

EPS Current Est	$-0.22	EPS Next Est	$0.6
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FENC	$7.55	+0.80%	463.81K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FENC	$7.55	+0.8%	463.81K
3
4
5
6

FENC

FENC

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Fennec Pharmaceuticals Inc. Data in Excel

Get Fennec Pharmaceuticals Inc. Data in Excel